Mesoblast Ltd Stock News

For bold investors, there are few opportunities as exciting as chasing 10x returns in the stock market. Make no mistake about it, the stock market offers up multiple opportunities to turn $1 into $10

Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.

Mesoblast Limited (MESO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in

The FDA has rejected Mesoblast's cell therapy candidate for pediatric acute graft versus host disease, causing the stock to decline. Mesoblast is an old company located in Australia, which may impact

Mesoblast (MESO), Coinbase (COIN), Western Gas (WES), JAKKS Pacific (JAKK), and Brinker International (EAT) have the potential to outperform in the seven-day period.

Mesoblast Limited (NASDAQ:MESO ) Q4 2023 Results Conference Call August 30, 2023 6:30 PM ET Company Participants Dr. Silviu Itescu - Chief Executive Officer Dr. Eric Rose - Chief Medical Officer Andre

Several analysts have recently downgraded their positions on the pharmaceutical stock. Mesoblast focuses on therapies derived from the cells of the bone marrow from healthy donors.

Mesoblast focuses on therapies to treat autoimmune disorders. The company's resubmission of Ryoncil was given a Complete Response Letter by the FDA.

The U.S. Food and Drug Administration had rejected Mesoblast's , cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transp

IAS, MESO and PCOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 26, 2023.

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND